Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 18/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.55 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.47 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22893672 | 0.88 | ITGAV (0.58) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL22893606 | 0.86 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL29416481 | 0.83 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL21329049 | 0.83 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL21328584 | 0.82 | ITGAV (0.60) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL24363119 | 0.82 | ITGB3 (0.73) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL21329736 | 0.82 | ITGAV (0.60) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL21329134 | 0.82 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL7122150 | 0.82 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL21330082 | 0.81 | ITGAV (0.52) | ITGAVITGB3ITGB6ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 11/4885ITGB6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.